Research analysts at Canaccord Genuity assumed coverage on shares of CORONADO BIOSCIENCES INC (NASDAQ: CNDO) in a report released on Monday, TheFlyOnTheWall.com reports. The firm set a “buy” rating on the stock.
The analysts wrote, “We are initiating coverage of Coronado with a BUY rating and an $18 price target. The key value driver is TSO (Trichuris suis ova), a novel biologic composed of pig whipworm eggs currently in two randomized, placebo-controlled Phase 2 trials for Crohn’s disease. We like the novel mechanism (hygiene hypothesis rationale), positive single-arm data and physician feedback that handicaps a high likelihood of success for the upcoming data, which should provide a key stock catalyst in H2. We model for peak TSO sales in the U.S. of ~$1B in 2028, with TSO in other indications (ulcerative colitis, multiple sclerosis, autism)/territories and the second pipeline product CNDO-109 serving as a free-call option.”
CORONADO BIOSCIENCES INC (NASDAQ: CNDO) traded up 4.97% on Monday, hitting $9.71. CORONADO BIOSCIENCES INC has a 52-week low of $4.00 and a 52-week high of $9.60. The stock’s 50-day moving average is currently $7.97. The company’s market cap is $252.7 million.
CORONADO BIOSCIENCES INC (NASDAQ: CNDO) last released its earnings data on Thursday, March 14th. The company reported ($0.36) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.27) by $0.09. Analysts expect that CORONADO BIOSCIENCES INC will post $-1.13 EPS for the current fiscal year.
A number of other firms have also recently commented on CNDO. Analysts at MLV Capital raised their price target on shares of CORONADO BIOSCIENCES INC from $10.00 to $14.00 in a research note to investors on Thursday, March 14th. They now have a “buy” rating on the stock. Separately, analysts at Piper Jaffray initiated coverage on shares of CORONADO BIOSCIENCES INC in a research note to investors on Friday, March 1st. They set an “overweight” rating and a $17.00 price target on the stock. Finally, analysts at Roth Capital reiterated a “buy” rating on shares of CORONADO BIOSCIENCES INC in a research note to investors on Tuesday, January 22nd. They now have a $24.00 price target on the stock.
Six research analysts have rated the stock with a buy rating, The stock currently has a consensus rating of “Buy” and an average price target of $15.60.
Coronado Biosciences, Inc. is a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the treatment of autoimmune diseases and cancer.